Arch. Pharm. Chem. Life Sci. 2005, 338, 502−505
Quinazoline Derivatives as EGFR Tyrosine Kinase Inhibitors
505
cell line, which highly overexpresses EGFR. For compari-
son, the inhibitory activity of PD153035 under our assay
conditions was inserted into the data set, and the biological
data of Erlotinib (TracevaTM) from the previous literature
were also inserted into Table 1 for indirect comparison [18].
Acknowledgments
This work was supported by the Korea Institute of Science
and Technology (2E17073).
References
Among the 4-haloanilinoquinazolines, at first, 4-iodoanilin-
oquinazoline (3c) showed better potencies (CI50 ϭ 1.66 nM)
and the other two compounds (3a and 3b) showed less in-
hibitory activities (IC50 ϭ 10.08 and 28.89 nM, respectively)
than both PD153035 and Erlotinib (CI50 ϭ 6.10 and 3.69
nM, respectively) against the isolated enzyme. Against the
growth of the A431 cell line, all 4-haloanilinoquinazolines
[1] M. Yamada, T. Ikeuchi, H. Hatanaka, Prog. Neurobiol. 1997,
51, 19Ϫ37.
[2] K. Hickey, D. Grehan, I. M. Reid, S. O’Briain, T. N. Walsh, T.
P. J. Hennessy, Cancer 1994, 74, 1693Ϫ1698.
[3] D. W. Fry, A. J. Kraker, A. McMichael, L. A. Ambroso, J. M.
Nelson, W. R. Leopold, R. W. Connors, A. J. Bridges, Science
1994, 265, 1093Ϫ1095.
(3aϪc) showed relatively potent growth inhibition (GI50
ϭ
[4] A. J. Bridges, H. Zhou, D. R. Cody, G. W. Rewcastle, A.
McMichael, H. D. H. Showalter, D. W. Fry, A. J. Kraker, W.
A. Denny, J. Med. Chem. 1996, 39, 267Ϫ276.
1.99Ϫ2.63 µM), whereby 4-iodoanilinoquinazoline (3c,
GI50 ϭ 1.99 µM) appears to be the best inhibitor and was
as potent as Erlotinib (GI50 ϭ 1.55 µM) although less
potent than PD153035 (GI50 ϭ 1.03 µM). However, the
4-ethynylanilino compound (3e), the rigidified analogue of
Erlotinib, showed less potency (GI50 ϭ 4.74 µM) against
the growth of the A431 cell line. It was, however, not tested
against the isolated enzyme.
[5] B. D. Palmer, T. Trumpp-Kallmeyer, D. W. Fry, J. M. Nelson,
H. D. H. Showalter, W. A. Denny, J. Med. Chem. 1997, 40,
1519Ϫ529.
[6] A. Wissner, D. M. Berger, D. H. Boschelli, M. B. Floyd Jr., L.
M. Greenberger, B. C. Gruber, B. D. Johnson et al., J. Med.
Chem. 2000, 43, 3244Ϫ3256.
[7] J. B. Small, G. W. Rewcastle, J. A. Loo, K. D. Greis, O. H.
Chan, E. I. Reyner, E. Lipka et al., J. Med. Chem. 2000, 43,
1380Ϫ1397.
All 4-haloanilinoquinazolines (3aϪc) were also evaluated
for their ability to inhibit two other human cancer cell lines,
for their selectivity: HCT116 (colon cancer) and SNU638
(stomach cancer), which express low levels of EGFR; the
data was also inserted in Table 1. With respect to the cell
assays, it is evident that each compound is a better inhibitor
of the A431 than the HCT116 and SNU638 cell lines, as
shown in Table 1. This is consistent with the mechanism of
growth inhibition being largely due to the targeting of the
EGFR. Of all compounds tested, 4-bromoanilinoquinazo-
line (3b) showed better selectivity (more than six-fold) for
A431 than the two other compounds (3a and 3c), while it
is a less potent inhibitor against the isolated EGFR enzyme.
[8] H.-R. Tsou, N. Mamuya, B. D. Johnson, M. F. Reich, B. C.
Gruber, F. Ye, R. Nilakantan et al., J. Med. Chem. 2001, 44,
2719Ϫ2734.
[9] J. Y. Lee, Y. K. Park, S. H. Seo, I.-S. So, H.-K. Chung, B.-S.
Yang, S. J. Lee, H. Park, Y. S. Lee, Arch. Pharm. Pharm. Med.
Chem. 2001, 334, 357Ϫ360.
[10] J. Y. Lee, Y. K. Park, S. H. Seo, B.-S. Yang, H. Park, Y. S. Lee,
Arch. Pharm. Pharm. Med. Chem. 2002, 335, 487Ϫ494.
[11] A. Bridges, J. Chem. Rev. 2001, 101, 2541Ϫ2571.
[12] A. J. Barker, K. H. Gibson, W. Grundy, A. A. Godfrey, J. J.
Barlow, M. P. Healy, J. R. Woodburn et al., Bioorg. Med. Chem.
Lett. 2001, 11, 1911Ϫ1914.
[13] J. Dowell, J. D. Minna, P. Kirkpatrick, Nat. Rev. Drug Dis-
covery 2005, 4, 13Ϫ14. R. Perez-Soler, A. Chachoua, L. A.
Hammond, E. K. Rowinsky, M. Huberman, D. Karp, J. Rigas
et al., J. Clin. Oncol. 2004, 22, 3238Ϫ3247.
In conclusion, we prepared the 7,8-bis(methoxymethyl)-7,8-
dihydro-[1,4]dioxino[2,3-g]quinazolines (3aϪc) and the rig-
idified analogue (3e) of Erlotinib (TracevaTM) to probe the
effect of rigidification of substituents on the inhibition of
EGFR tyrosine kinase and on the growth inhibition of three
human tumor cell lines. Among them, 4-iodoanilinoquina-
zoline (3c) was most potent against the isolated enzyme and
showed potent antitumor activity nearly comparable to that
of Erlotinib, but the rigidified analogue (3e) was found to
be less potent than expected. This result implicates that the
rigidification of substituents of Erlotinib (TracevaTM) re-
sulted in the decreased effect on the growth inhibition of
the tumor cell lines.
[14] M. W. Kunkel, K. E. Hook, C. T. Howard, S. Przybranowski,
B. J. Roberts, W. L. Elliott, W. R. Leopold, Invest. New Drugs
1996, 13, 295Ϫ302.
´
[15] A. G. Suarez, Tetrahedron Lett. 1999, 40, 3523Ϫ3526.
[16] P. M. Heertjes, B. J. Knape, H. C. A. van Beek, K. van den
Boogaart, J. Chem. Soc. 1957, 3445Ϫ3447.
[17] S. Caddick, V. M. Delisser, V. E. Doyle, S. Khan, Tetrahedron
1999, 55, 2737Ϫ2754.
[18] A. Wissner, M. B. Floyd, S. K. Rabindran, R. Nilakantan,
L. M. Greenberger, R. Shen, Y.-F. Wang, H.-R. Tsou, Bioorg.
Med. Chem Lett. 2002, 12, 2893Ϫ2897.
2005 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim